EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy, safety, and tolerability of antifibrotic agents in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis

Javier Narváez, Martí Aguilar-Coll, Montserrat Roig-Kim, Judith Palacios-Olid, Pol Maymó-Paituvi, Laia de Daniel-Bisbe, Dídac LLop

Autoimmunity Reviews · 2025

DOI: 10.1016/j.autrev.2025.103804 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Autoimmunity Reviews, 2025. Verfasst von Javier Narváez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Hospital Universitario de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. Electronic addr…. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Pyridones, Arthritis, Rheumatoid, Antifibrotic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the efficacy, safety, and tolerability of antifibrotic agents, nintedanib and pirfenidone, in the treatment of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). METHODS: A systematic literature review was conducted following PRISMA and MOOSE guidelines. Studies assessing nintedanib or pirfenidone in RA-ILD were included. A meta-analysis was performed using a random-effects model. RESULTS: Six studies (2 randomized controlled trials and 4 observational) involving 270 RA-ILD patients met the inclusion criteria. In total, 148 received nintedanib and 122 received pirfenidone. Nearly 70 % had a usual interstitial pneumonia pattern. The pooled analysis revealed a mean FVC decline of -68.97 mL/year (95 % CI: -104.85 to -32.49; p < 0.001) and a mean difference of 1.15 % (p = 0.33; after excluding influential studies: -0.28, p = 0.54). Their impact on %pDLCO has been less extensively evaluated, with a mean difference of -1.76 % (p = 0.36; after excluding influential studies: effect size -3.78, p < 0.001). The changes in pulmonary function tests were comparable between nintedanib and pirfenidone. Mortality rates ranged from 15 % to 35 %, with respiratory-specific mortality reported at 44 % to 100 %. Lung transplantation rates were 4-5 %. Antifibrotic therapy was associated with a pooled adverse event (AE) rate of 73 % (95 % CI: 0.38-0.97; p < 0.001), with gastrointestinal symptoms and hepatotoxicity being the most frequently reported. Treatment discontinuation due to AEs occurred in nearly 24 % of patients (95 % CI: 0.16-0.40; p < 0.001). CONCLUSION: Antifibrotic agents demonstrated stabilization of %pFVC, with less robust evidence for %pDLCO in RA-ILD. Nearly one quarter of patients discontinued therapy due to AEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung Diseases, InterstitialPyridonesArthritis, RheumatoidAntifibrotic AgentsIndolesHumansTreatment Outcome

Stichwörter der Autor:innen

AntifibroticsInterstitial lung diseasesNintedanibPirfenidoneRheumatoid arthritis

Substanzen

PyridonespirfenidonenintedanibAntifibrotic AgentsIndoles

Autor:innen und Institutionen

  • Department of Rheumatology, Hospital Universitario de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. Electronic address: fjnarvaez@bellvitgehospital.cat.
  • Department of Rheumatology, Hospital Universitario de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
  • Unitat de Recerca de Lípids i Arteriosclerosi, Universitat Rovira i Virgili, Reus, Institut d'Investigació Sanitària Pere Virgili, Tarragona, Spain.

Zitieren

APA

Narváez, J., Aguilar-Coll, M., Roig-Kim, M., Palacios-Olid, J., Maymó-Paituvi, P., de Daniel-Bisbe, L., & LLop, D. (2025). Efficacy, safety, and tolerability of antifibrotic agents in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis. Autoimmunity Reviews. https://doi.org/10.1016/j.autrev.2025.103804

Vancouver

Narváez J, Aguilar-Coll M, Roig-Kim M, Palacios-Olid J, Maymó-Paituvi P, de Daniel-Bisbe L, et al. Efficacy, safety, and tolerability of antifibrotic agents in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis. Autoimmunity Reviews. 2025. doi:10.1016/j.autrev.2025.103804

BibTeX
@article{Narvez2025,
  author = {Narváez, Javier and Aguilar-Coll, Martí and Roig-Kim, Montserrat and Palacios-Olid, Judith and Maymó-Paituvi, Pol and de Daniel-Bisbe, Laia and LLop, Dídac},
  title = {Efficacy, safety, and tolerability of antifibrotic agents in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis},
  journal = {Autoimmunity Reviews},
  year = {2025},
  doi = {10.1016/j.autrev.2025.103804}
}
Kostenlos starten →